Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I

H. Lundbeck A/S has initiated phase I clinical trials with the
pharmaceutical candidate Lu AA24493 to investigate safety,
tolerability and the pharmacokinetic profile of the compound in
patients suffering from acute ischemic stroke.

Lu AA24493 is a novel carbamoylated form of human erythropoietin
(EPO) - a modification of EPO that results in loss of haematopoietic
effects but maintains the tissue protective effect. These tissue
protective effects translate to very positive effects in a number of
animal models for neuronal damage including models for cerebral
stroke."There is a significant medical need for effective treatments within
stroke and Lu AA24493 offers a novel approach to a disease with few
treatment options today," says Peter Høngaard Andersen, Head of
Research at Lundbeck. He continues: "We are very pleased that our
scientists have successfully advanced Lu AA24493 to clinical
development."

Lu AA24493 was developed as part of the collaboration between H.
Lundbeck A/S and Warren Pharmaceuticals, Inc. and it is licensed from
Warren Pharmaceuticals under the license agreement that the companies
announced in 2002. Under that agreement Lundbeck holds worldwide
rights for indications related to the central nervous system.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.

Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79              +45 36 43 26 38
+1 201 350 0187








                      ________________________

Stock Exchange Release No 298 - 18 October 2007

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com